- Home
- PULM vs GRCE Comparison
PULM vs GRCE Comparison
Compare PULM & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- GRCE
- Stock Information
- Founded
- PULM 2003
- GRCE 2002
- Country
- PULM United States
- GRCE United States
- Employees
- PULM N/A
- GRCE N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- GRCE
- Sector
- PULM Health Care
- GRCE
- Exchange
- PULM Nasdaq
- GRCE NYSE
- Market Cap
- PULM 30.9M
- GRCE 32.1M
- IPO Year
- PULM N/A
- GRCE N/A
- Fundamental
- Price
- PULM $6.71
- GRCE $2.23
- Analyst Decision
- PULM
- GRCE Strong Buy
- Analyst Count
- PULM 0
- GRCE 1
- Target Price
- PULM N/A
- GRCE $12.00
- AVG Volume (30 Days)
- PULM 22.2K
- GRCE 32.8K
- Earning Date
- PULM 03-21-2025
- GRCE 05-15-2025
- Dividend Yield
- PULM N/A
- GRCE N/A
- EPS Growth
- PULM N/A
- GRCE N/A
- EPS
- PULM N/A
- GRCE N/A
- Revenue
- PULM $7,806,000.00
- GRCE N/A
- Revenue This Year
- PULM N/A
- GRCE N/A
- Revenue Next Year
- PULM $134.88
- GRCE N/A
- P/E Ratio
- PULM N/A
- GRCE N/A
- Revenue Growth
- PULM 6.96
- GRCE N/A
- 52 Week Low
- PULM $1.68
- GRCE $2.07
- 52 Week High
- PULM $10.40
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- PULM 41.18
- GRCE N/A
- Support Level
- PULM $7.16
- GRCE N/A
- Resistance Level
- PULM $7.33
- GRCE N/A
- Average True Range (ATR)
- PULM 0.53
- GRCE 0.00
- MACD
- PULM -0.11
- GRCE 0.00
- Stochastic Oscillator
- PULM 0.72
- GRCE 0.00
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.